Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 39-45

  Bell, Lucy C K ^a   Breen, Ronan ^b   Miller, Robert F ^a   Noursadeghi, Mahdad ^a   Lipman, Marc ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

HIV; Immune reconstitution; IRIS; Mycobacteria; Paradoxical reaction; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; META ANALYSIS; NONHUMAN; PARADOXICAL DRUG REACTION; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT RESPONSE; TUBERCULOSIS; ADVERSE EFFECTS; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; MIXED INFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; RISK FACTORS; TUBERCULOSIS;

EID: 84925258821     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.030     Document Type: Review

References (77)

1. Cheng V.C., Ho P.L., Lee R.A., Chan K.S., Chan K.K., Woo P.C., et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002, 21:803-809.
2. Cheng S.L., Wang H.C., Yang P.C. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2007, 11:1290-1295.
3. Hawkey C.R., Yap T., Pereira J., Moore D.A., Davidson R.N., Pasvol G., et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis 2005, 40:1368-1371.
4. Campbell I.A., Dyson A.J. Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle 1977, 58:171-179.
5. Breen R., Smith C., Bettinson H., Dart S., Bannister B., Johnson M., et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004, 59:704-707.
6. Narita M., Ashkin D., Hollender E.S., Pitchenik A.E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998, 158:157-161.
7. Jung J.W., Shin J.W., Kim J.Y., Park I.W., Choi B.W., Seo J.S., et al. Risk factors for development of paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pleural tuberculosis. Tohoku J Exp Med 2011, 223:199-204.
8. Cheng V.C., Yam W.C., Woo P.C., Lau S.K., Hung I.F., Wong S.P., et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003, 22:597-602.
9. Nienhuis W.A., Stienstra Y., Abass K.M., Tuah W., Thompson W.A., Awuah P.C., et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012, 54:519-526.
10. Walker N.F., Meintjes G., Wilkinson R.J. HIV-1 and the immune response to TB. Future Virol 2013, 8:57-80.
11. Sonnenberg P., Glynn J.R., Fielding K., Murray J., Godfrey-Faussett P., Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase?. A retrospective cohort study in South African gold miners. J Infect Dis 2005, 191:150-158.
12. Gupta A., Wood R., Kaplan R., Bekker L.G., Lawn S.D. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One 2012, 7:e34156.
13. Müller M., Wandel S., Colebunders R., Attia S., Furrer H., Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:251-261.
14. Haddow L.J., Moosa M.Y., Mosam A., Moodley P., Parboosing R., Easterbrook P.J. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS One 2012, 7:e40623.
15. Lawn S.D., Bekker L.G., Miller R.F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361-373.
16. Lawn S.D., Wilkinson R.J., Lipman M.C.I., Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008, 177:680-685.
17. Breen R.A., Smith C.J., Cropley I., Johnson M.A., Lipman M.C. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?. AIDS 2005, 19:1201-1206.
18. Worodria W., Menten J., Massinga-Loembe M., Mazakpwe D., Bagenda D., Koole O., et al. Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther 2012, 17:841-848.
19. Valin N., Pacanowski J., Denoeud L., Lacombe K., Lalande V., Fonquernie L., et al. Risk factors for "unmasking immune reconstitution inflammatory syndrome" presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS 2010, 24:1519-1525.
20. French M.A., Mallal S.A., Dawkins R.L. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992, 6:1293-1297.
21. Phillips P., Bonner S., Gataric N., Bai T., Wilcox P., Hogg R., et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005, 41:1483-1497.
22. Afghani B., Lieberman J.M. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis 1994, 19:1092-1099.
23. Lawn S.D., Myer L., Bekker L.G., Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335-341.
24. Luetkemeyer A.F., Kendall M.A., Nyirenda M., Wu X., Ive P., Benson C.A., et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr 2014, 65:423-428.
25. Naidoo K., Yende-Zuma N., Padayatchi N., Naidoo K., Jithoo N., Nair G., et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012, 157:313-324.
26. Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
27. Park J.A., Park S.S., Park S.E. A paradoxical reaction during antituberculosis therapy for congenital tuberculosis. Int J Infect Dis 2009, 13:e279-e281.
28. Meintjes G., Lawn S.D., Scano F., Maartens G., French M.A., Worodria W., et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
29. Worodria W., Massinga-Loembe M., Mayanja-Kizza H., Namaganda J., Kambugu A., Manabe Y.C., et al. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol 2011, 2011:758350.
30. Haddow L.J., Easterbrook P.J., Mosam A., Khanyile N.G., Parboosing R., Moodley P., et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 2009, 49:1424-1432.
31. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012, 54:1364-1372. HIV-CAUSAL Collaboration.
32. Breton G., Duval X., Estellat C., Poaletti X., Bonnet D., Mvondo Mvondo D., et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004, 39:1709-1712.
33. Blanc F.X., Sok T., Laureillard D., Borand L., Rekacewicz C., Nerrienet E., et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
34. Bonnet M., Baudin E., Jani I.V., Nunes E., Verhoustraten F., Calmy A., et al. Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome. PLoS One 2013, 8:e84585.
35. Marais S., Meintjes G., Pepper D.J., Dodd L.E., Schutz C., Ismail Z., et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013, 56:450-460.
36. Conesa-Botella A., Loembé M.M., Manabe Y.C., Worodria W., Mazakpwe D., Luzinda K., et al. Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome. J Acquir Immune Defic Syndr 2011, 58:463-468.
37. Kim T.S., Hufford M.M., Sun J., Fu Y.X., Braciale T.J. Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med 2010, 207:1161-1172.
38. Andrade B.B., Singh A., Narendran G., Schechter M.E., Nayak K., Subramanian S., et al. Mycobacterial antigen driven activation of CD14++CD16-monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog 2014, 10:e1004433.
39. Perrin FM, Breen RA, Lipman MC, Shorten RJ, Gillespie SH, McHugh TD. Is there a relationship between Mycobacterium tuberculosis strain type and TB paradoxical reaction? Thorax 2005;60:706-7.
40. Simonney N., Dewulf G., Herrmann J.L., Gutierrez M.C., Vicaut E., Boutron C., et al. Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (Edinb) 2008, 88:453-461.
41. Price P., Morahan G., Huang D., Stone E., Cheong K.Y., Castley A., et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043-2047.
42. Beck J.S., Potts R.C., Kardjito T., Grange J.M. T4 lymphopenia in patients with active pulmonary tuberculosis. Clin Exp Immunol 1985, 60:49-54.
43. Roberts T., Beyers N., Aguirre A., Walzl G. Immunosuppression during active tuberculosis is characterized by decreased interferon-γ production and CD25 expression with elevated forkhead box P3, transforming growth factor-β, and interleukin-4 mRNA levels. J Infect Dis 2007, 195:870-878.
44. Barber D.L., Mayer-Barber K.D., Antonelli L.R., Wilson M.S., White S., Caspar P., et al. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 2010, 116:3485-3493.
45. Guihot A., Bourgarit A., Carcelain G., Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011, 32:131-137.
46. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
47. Pakker N.G., Notermans D.W., De Boer R.J., Roos M.T., Wolf F.D., Hill A., et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4:208-214.
48. Imami N., Antonopoulos C., Hardy G.A., Gazzard B., Gotch F.M. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 1999, 15:1499-1508.
49. Zamir E., Hudson H., Ober R.R., Kumar S.K., Wang R.C., Read R.W., et al. Massive mycobacterial choroiditis during highly active antiretroviral therapy: another immune-recovery uveitis?. Ophthalmology 2002, 109:2144-2148.
50. Bourgarit A., Carcelain G., Martinez V., Lascoux C., Delcey V., Gicquel B., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006, 20:F1-F7.
51. Wilkinson K.A., Meintjes G., Seldon R., Goliath R., Wilkinson R.J. Immunological characterisation of an unmasking TB-IRIS case. South Afr Med J 2012, 102:512-517.
52. Meintjes G., Wilkinson K.A., Rangaka M.X., Skolimowska K., van Veen K., Abrahams M., et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008, 178:1083-1089.
53. Mahnke Y.D., Greenwald J.H., Dersimonian R., Roby G., Antonelli L.R., Sher A., et al. Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012, 119:3105-3112.
54. Tadokera R., Meintjes G., Skolimowska K.H., Wilkinson K.A., Matthews K., Seldon R., et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 2011, 37:1248-1259.
55. Tadokera R., Meintjes G.A., Wilkinson K.A., Skolimowska K.H., Walker N., Friedland J.S., et al. Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2014, 44:127-136.
56. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
57. Barber D.L., Andrade B.B., Sereti I., Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012, 10:150-156.
58. Grant P.M., Komarow L., Lederman M.M., Pahwa S., Zolopa A.R., Andersen J., et al. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis 2012, 206:1715-1723.
59. Wood R., Middelkoop K., Myer L., Grant A.D., Whitelaw A., Lawn S.D., et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007, 175:87-93.
60. Von Reyn C.F., Kimambo S., Mtei L., Arbeit R.D., Maro I., Bakari M., et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011, 15:1087-1092.
61. Rana F.S., Hawken M.P., Mwachari C., Bhatt S.M., Abdullah F., Ng'ang'a L.W., et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000, 24:23-29.
62. Nambuya A., Sewankambo N., Mugerwa J., Goodgame R., Lucas S. Tuberculous lymphadenitis associated with human immunodeficiency virus (HIV) in Uganda. J Clin Pathol 1988, 41:93-96.
63. Rivoisy C., Amrouche L., Carcelain G., Séréni D., Bourgarit A. Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 2011, 78:312-315.
64. Britton W.J., Lockwood D.N. Leprosy. Lancet 2004, 363:1209-1219.
65. Teles R.M., Graeber T.G., Krutzik S.R., Montoya D., Schenk M., Lee D.J., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013, 339:1448-1453.
66. Roca F.J., Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013, 153:521-534.
67. Meintjes G., Wilkinson R.J., Morroni C., Pepper D.J., Rebe K., Rangaka M.X., et al. Randomized placebo-controlled trial of prednisone for paradoxical TB-associated immune reconstitution inflammatory syndrome. AIDS 2010, 24:2381-2390.
68. Meintjes G., Skolimowska K.H., Wilkinson K.A., Matthews K., Tadokera R., Conesa-Botella A., et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012, 186:369-377.
69. Mayer-Barber K.D., Andrade B.B., Oland S.D., Amaral E.P., Barber D.L., Gonzales J., et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511:99-103.
70. Barber D.L., Andrade B.B., McBerry C., Sereti I., Sher A. Role of IL-6 in Mycobacterium avium-associated immune reconstitution inflammatory syndrome. J Immunol 2014, 192:676-682.
71. Antonelli L.R., Mahnke Y., Hodge J.N., Porter B.O., Barber D.L., DerSimonian R., et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010, 116:3818-3827.
72. Bourgarit A., Carcelain G., Samri A., Parizot C., Lafaurie M., Abgrall S., et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol 2009, 183:3915-3923.
73. Bekker L.G., Maartens G., Steyn L., Kaplan G. Selective increase in plasma tumor necrosis factor-α and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998, 178:580-584.
74. Tran H.T., Van den Bergh R., Loembé M.M., Worodria W., Mayanja-Kizza H., Colebunders R., et al. Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2013, 27:1725-1734.
75. Tan D.B., Lim A., Yong Y.K., Ponnampalavanar S., Omar S., Kamarulzaman A., et al. TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease. AIDS 2011, 25:1455-1460.
76. Pean P., Nerrienet E., Madec Y., Borand L., Laureillard D., Fernandez M., et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012, 119:3315-3320.
77. Conradie F., Foulkes A.S., Ive P., Yin X., Roussos K., Glencross D.K., et al. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr 2011, 58:309-318.